Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects.
This paper concerns certain questions which arose during the analysis of a trial showing positive effects of tacrine in Alzheimer's disease. Cognitive improvement occurred during the first two weeks, reached a maximum at one month and was maintained during the rest of the three-month treatment period. Rebound effects were not detected in any of the key outcome variables, but were suggested by one of the supporting cognitive tests and other measures. Practice effects occurred on tests which were repeated at short intervals or too frequently. The paper discusses the significance of these findings for the interpretation of other trials and for practical management.
Eagger
S
S
Institute of Psychiatry, Denmark Hill, London.
Morant
N
N
Levy
R
R
Sahakian
B
B
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology*; D001288:Attention / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008609:Mental Status Schedule; D009483:Neuropsychological Tests; D011597:Psychomotor Performance / Q000187:drug effects; D013619:Tacrine / Q000009:adverse effects / Q000627:therapeutic use*
D013619:Tacrine